Teleflex Awarded Central Venous Access, Arterial Access Agreements with Premier


WAYNE, PA — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has been awarded group purchasing agreements for Central Venous Access and Arterial Access with Premier, effective July 1.

Premier has awarded Teleflex a multi-source Central Venous Access Product and sole source Arterial Catheter agreement for National members. A sole-source Central Venous Access Product agreement was awarded for Ascend members.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 175,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

These new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for CVC and Arterial Vascular Access Products.

“Teleflex works to develop Arrow® Brand vascular access products that are designed to equally benefit clinicians and patients, help protect against vascular access related complications like infection, thrombosis, and tip malposition, and help clinicians follow independent third-party vascular access guidelines” said Jake Newman, President and General Manager, Teleflex Vascular. “As the market leader in CVCs and Arterial devices1-2, we are pleased to offer Premier members one of the broadest portfolios of central access and arterial access products available.”

READ:  Vanguard Announces Plans to Launch Two New Active Bond Funds

Teleflex, through its Arrow® Brand of CVC products, has been innovating for more than four decades to help healthcare providers optimize patient outcomes, minimize the risk of central line-associated infections (CLABSI), and efficiently streamline insertion procedures.

Antimicrobial Arrowg+ard Blue Plus® CVCs are the only full-spectrum antimicrobial CVCs that protect against both gram-positive and gram-negative bacteria, fungi, and demonstrate a 67-100% reduction in CLABSI3-6.

Combined with antimicrobial Arrowg+ard Blue Plus® CVCs, Arrow® ErgoPack® Systems help make it easy to:

  • Standardize vascular access across a system
  • Maintain a high standard of patient care
  • Control costs and risks from infections

Arrow® ErgoPack® Systems help clinicians comply with third-party guideline recommendations7-10, including:

  • CDC Category 1A &1B Recommendations
  • SHEA Guidelines
  • INS Standards of Practice
  • OSHA Bloodborne Pathogens Standard
READ:  XyloCor Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy

The Arrow® Brand of arterial access products contains a comprehensive portfolio of catheters designed to accommodate a variety of insertion location and placement techniques.


  1. IMS Data. Data based on 2019 Q4 Total Acute CVC market unit share for Teleflex. 2019.
  2. IMS Data. Data based on 2019 Q4 Total Arterial market unit share for Teleflex. 2019.
  3. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a Second-Generation Venous Catheter Impregnated with Chlorhexidine and Silver Sulfadiazine of Central Catheter-Related Infections. Ann Intern Medicine. 2005; 143: 570-80. Sponsored by Arrow (Teleflex).
  4. Lorente L, Lecuona M, Jimenez A, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters save costs. American Journal of Infection Control. 2014; 42: 321-4.
  5. Lorente L, Lecuona M, Jimenez A, et al. Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access. American Journal of Infection Control. 2014; 42: 1130-2.
  6. Lorente, L, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters are efficient even at subclavian sites without tracheostomy. American journal of infection control. 2016; 44(12): 1526-29. Zimlichman, E, et al.
  7. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.
  8. Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2014 July; 35(7): 753-71.
  9. Gorski L, Hadaway L, Hagle ME, McGoldrick M, et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2016; Jan 39(1S).
  10. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. Accessed on February 12, 2020.
READ:  Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.